-
Important news
-
News
-
Shenzhen
-
China
-
World
-
Opinion
-
Sports
-
Kaleidoscope
-
Photo Highlights
-
Business
-
Markets
-
Business/Markets
-
World Economy
-
Speak Shenzhen
-
Leisure Highlights
-
Culture
-
Travel
-
Entertainment
-
Digital Paper
-
In depth
-
Weekend
-
Lifestyle
-
Diversions
-
Movies
-
Hotels
-
Special Report
-
Yes Teens
-
News Picks
-
Tech and Science
-
Glamour
-
Campus
-
Budding Writers
-
Fun
-
Futian Today
-
Advertorial
-
CHTF Special
-
FOCUS
-
Guide
-
Nanshan
-
Hit Bravo
-
People
-
Person of the week
-
Majors Forum
-
Shopping
-
Investment
-
Tech and Vogue
-
Junior Journalist Program
-
Currency Focus
-
Food Drink
-
Restaurants
-
Yearend Review
-
QINGDAO TODAY
在线翻译:
szdaily -> China -> 
Standardized overall treatment for breast cancer
    2019-04-01  08:53    Shenzhen Daily

THE country is moving to promote a package of breast cancer prevention and treatment standards across the country, hoping to further prolong patients’ survival time and narrow the diagnosis and treatment gap between urban and rural areas.

A series of guidelines covering breast cancer screening, early diagnosis and treatment, rational drug use, follow-up treatment and management of concomitant diseases was released Saturday at an ongoing cancer and health conference jointly held by the National Cancer Center (NCC), Cancer Foundation of China and Beijing Breast Disease Society.

Data released by the NCC in March 2018 showed that the mortality rate of breast cancer in China accounted for 16.5 percent of all cancers in females. As breast cancer continues to lay claim to top incidence rates both at home and abroad, its cure rate has been improving steadily in China, with the five-year survival rate reaching 83.2 percent between 2010 and 2014, up by 7.3 percent since 2000.

As survival time has been significantly prolonged, more patients have entered a chronic disease period, according to the guidelines for breast cancer follow-up and overall management of concomitant diseases, the first situation of its kind in China.

Common concomitant diseases of breast cancer include cardiovascular diseases, abnormal bone metabolism and depression. “Among elder patients, cardiovascular diseases have caused even more deaths than cancer itself,” said Ma Fei, executive chairman of the conference and expert from the NCC.

Under the dual effects of ovarian dysfunction and drugs, postmenopausal patients suffer a distinct drop in estrogen levels, which often results in an abnormal lipid amount in the blood and increases the risk of cardiovascular diseases, Ma explained.

In addition, a large number of patients will continue to receive endocrine therapy for five to 10 years after cancer treatment, which is often accompanied by abnormal bone metabolism, osteoporosis and even fractures.

The guidelines clearly require doctors, through interdisciplinary collaborations, to take into consideration a patient’s blood lipid level and bone density before giving endocrine therapy. It also suggests that doctors intervene to help patients quit smoking and drinking alcohol as well as avoid tumbles and serious body impacts according to the evaluation of their overall health condition.

(Xinhua)

深圳报业集团版权所有, 未经授权禁止复制; Copyright 2010, All Rights Reserved.
Shenzhen Daily E-mail:szdaily@szszd.com.cn